P
Puja Sakhuja
Researcher at Post Graduate Institute of Medical Education and Research
Publications - 146
Citations - 4661
Puja Sakhuja is an academic researcher from Post Graduate Institute of Medical Education and Research. The author has contributed to research in topics: Medicine & Liver biopsy. The author has an hindex of 31, co-authored 132 publications receiving 4022 citations. Previous affiliations of Puja Sakhuja include University of Delhi & Maulana Azad Medical College.
Papers
More filters
Journal ArticleDOI
Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)
Shiv Kumar Sarin,Ashok Kumar,John A. Almeida,Yogesh Chawla,Sheung Tat Fan,Hitendra Garg,H. Janaka de Silva,Saeed Hamid,Rajiv Jalan,Piyawat Komolmit,George K. K. Lau,Qing Liu,Kaushal Madan,Rosmawati Mohamed,Qin Ning,Salimur Rahman,Archana Rastogi,Stephen M. Riordan,Puja Sakhuja,Didier Samuel,Samir Shah,Barjesh Chander Sharma,Praveen Sharma,Yasuhiro Takikawa,Babu Ram Thapa,Chun-Tao Wai,Man-Fung Yuen +26 more
TL;DR: The original proposed definition of ACLF was found to withstand the test of time and identify a homogenous group of patients presenting with liver failure, which led to the development of the final AARC consensus.
Journal ArticleDOI
Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALT
Manoj Kumar,Shiv Kumar Sarin,Syed Hissar,Chandana Pande,Puja Sakhuja,Barjesh Chander Sharma,Ranjit Chauhan,Sujoy Bose +7 more
TL;DR: Use of ALT and HBV DNA levels without resorting to liver biopsy to define "inactive carrier state" in HBeAg(-) PNALT patients may miss histologically significant disease in a proportion of patients.
Journal ArticleDOI
Granulocyte Colony–Stimulating Factor Mobilizes CD34+ Cells and Improves Survival of Patients With Acute-on-Chronic Liver Failure
Vishal Garg,Hitendra Garg,Arshi Khan,Nirupama Trehanpati,Ashok Kumar,Barjesh Chander Sharma,Puja Sakhuja,Shiv Kumar Sarin +7 more
TL;DR: G-CSF therapy more than doubles the percentage of patients with ACLF who survive for 2 months; it also significantly reduces CTP, MELD, and SOFA scores and prevents the development of sepsis, hepatorenal syndrome, and hepatic encephalopathy.
Journal ArticleDOI
Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis.
Sanjay K. Satapathy,Sanjay Garg,Ranjeet Chauhan,Puja Sakhuja,Veena Malhotra,Barjesh Chander Sharma,Shiv Kumar Sarin +6 more
TL;DR: In patients with NASH, pentoxifylline therapy effectively achieved significant clinical and biochemical improvement with reduction in HOMAIR, possibly mediated through suppression of TNF-α.
Journal ArticleDOI
Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.
Gamal Shiha,Alaa Ibrahim,Ahmed Helmy,Shiv Kumar Sarin,Masao Omata,Ashok Kumar,David Bernstien,Hitushi Maruyama,Vivek A. Saraswat,Yogesh Chawla,Saeed Hamid,Zaigham Abbas,Pierre Bedossa,Puja Sakhuja,Mamun Elmahatab,Seng Gee Lim,Laurentius A. Lesmana,Jose D. Sollano,Jidong Jia,Bahaa Abbas,Ashraf Omar,Barjesh Chander Sharma,Diana A. Payawal,Ahmed Abdallah,Abdelhamid Serwah,Abdelkhalek Hamed,Aly Elsayed,Amany AbdelMaqsod,Tarek Hassanein,Ahmed Ihab,Hamsik GHaziuan,Nizar N. Zein,Manoj Kumar +32 more
TL;DR: Advances in the field are presented, and the APASL 2016 updated version on invasive and non-invasive assessment of hepatic fibrosis, which includes invasive methods (LB and hepatic venous pressure gradient measurements), blood tests, conventional radiological methods, elastography techniques and cost-effectiveness of liver fibrosis assessment methods are presented.